Controversies in the adjuvant treatment of breast cancer: new adjuvant endocrine treatment strategies
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/15/suppl_4/iv23/450420/mdh901.pdf
Reference27 articles.
1. Tamoxifen for early breast cancer: an overview of the randomised trials;Lancet,1998
2. Superior efficacy of letrozole versus tamoxifen as first line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group;Mouridsen;J Clin Oncol,2001
3. Anastrozole versus tamoxifen as first line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study;Bonneterre;J Clin Oncol,2000
4. Anastrozole is superior to tamoxifen as first line therapy for advanced breast carcinoma in postmenopauxsal women: results of a North American multicenter randomized trial;Nabholtz;J Clin Oncol,2000
5. First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Tamoxifen citrate loaded biodegradable poly(sebacic acid-co- ricinoleic acid) microparticles, in vitro characterization;Journal of Drug Delivery Science and Technology;2011
2. Sequential Therapy With Tamoxifen and Aromatase Inhibitors in Early-Stage Postmenopausal Breast Cancer: A Review of the Evidence;Oncology Nursing Forum;2008-06-30
3. Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies;Expert Opinion on Pharmacotherapy;2006-12
4. From adjuvant to preventive breast cancer treatment: bridging the gap over troubled waters;Annals of Oncology;2006-06
5. Moving Away From the “One Shoe Fits All” Strategy: The Key to Future Progress in Chemotherapy;Journal of Clinical Oncology;2005-03-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3